Global multi-omics leader Novogene is establishing its first Australian laboratory at Cabrini Health, bringing advanced genomic capabilities closer to Australian patients and researchers, reducing the wait for genomic test results that can inform cancer treatment decisions, and accelerating access to personalised treatment and precision diagnostic testing.
The joint laboratory will be strategically located within the clinical and cancer research precinct at Cabrini Malvern. Expected to open in 2027, it will become Australia’s first genomics laboratory co-located within a private hospital.
Novogene’s expansion into Australia marks a significant boost to Victoria’s precision medicine capabilities, bringing industry-leading expertise, technologies and workflows in high-throughput sequencing and advanced multi-omics.
“We’ve been fortunate to secure significant investment, including a $10 million grant from the PMF Foundation and a $5 million Australian Government grant, to establish a precision oncology programme that will help patients access genomic testing and personalised treatments,” Cabrini Chief Executive Sue Williams said.
Cabrini’s cancer services deliver approximately 30,000 treatments and 4,000 diagnoses each year, while its clinical trials programme provides patients with access to innovative new therapies across approximately 100 active trials. By integrating genomic testing within the clinical environment, the laboratory is expected to enable faster turnaround from biopsy to genomic results, supporting more timely clinical decision-making and treatment initiation.
